⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DNTH News
Dianthus Therapeutics, Inc. Common Stock
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com
DNTH
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com
DNTH
Form 8-K
sec.gov
DNTH
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
globenewswire.com
DNTH
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
globenewswire.com
DNTH
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
globenewswire.com
DNTH
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
globenewswire.com
DNTH
Form 8-K
sec.gov
DNTH
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
globenewswire.com
DNTH
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
globenewswire.com
DNTH